Tirzepatide
Description
Tirzepatide represents the biggest breakthrough in obesity treatment in decades. Unlike earlier medications that target a single pathway, tirzepatide activates both GIP and GLP-1 receptors simultaneously, producing dramatic effects on appetite, blood sugar, and body weight. In clinical trials, participants lost up to 22.5% of their body weight—results previously achievable only through surgery. FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight loss, tirzepatide has become one of the most sought-after medications in history, with demand far exceeding supply. The compound works by mimicking natural gut hormones that signal fullness to the brain, reduce appetite, slow gastric emptying, and improve insulin sensitivity.
Certificate of Analysis
Every batch of Tirzepatide is independently lab-tested to a minimum of 98% purity. A Certificate of Analysis is available on request — contact us with your order or lot number and we'll send the COA for your specific batch.
Request a COAResearch Protocol
Full dose-by-dose reconstitution & dosing protocol for Tirzepatide.
View Research Protocol →Research protocol for this size is coming soon.
For laboratory and scientific research use only. Not medical advice.
For laboratory and research use only. Minimum 98% purity. Supplied in sterile, flip-top headspace vials for laboratory use. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. The purchaser accepts full responsibility for safe handling, storage and lawful use.